ORIGINAL ARTICLE

Higher reward value of starvation imagery in anorexia nervosa and association with the Val66Met *BDNF* polymorphismJ Clarke^{1,2}, N Ramoz^{1,2}, A-K Fladung³ and P Gorwood^{1,2}

Recent studies support the idea that abnormalities of the reward system contribute to onset and maintenance of anorexia nervosa (AN). Next to cues coding for overweight, other research suggest cues triggering the proposed starvation dependence to be pivotally involved in the AN pathogenesis. We assessed the characteristics of the cognitive, emotional and physiologic response toward disease-specific pictures of female body shapes, in adult AN patients compared with healthy control (HC) women. Frequency and amplitude of skin conductance response (SCR) in 71 patients with AN and 20 HC were registered during processing of stimuli of three weight categories (over-, under- and normal weight). We then assessed the role of the Val66Met *BDNF* polymorphism as a potential intermediate factor. AN patients reported more positive feelings during processing of underweight stimuli and more negative feelings for normal- and overweight stimuli. The SCR showed a group effect ($P=0.007$), AN patients showing overall higher frequency of the response. SCR within patients was more frequent during processing of underweight stimuli compared with normal- and overweight stimuli. The Met allele of the *BDNF* gene was not more frequent in patients compared with controls, but was associated to an increased frequency of SCR ($P=0.008$) in response to cues for starvation. A higher positive value of starvation, rather than more negative one of overweight, might more accurately define females with AN. The Met allele of the *BDNF* gene could partly mediate the higher reward value of starvation observed in AN.

Translational Psychiatry (2016) 6, e829; doi:10.1038/tp.2016.98; published online 7 June 2016

INTRODUCTION

Anorexia nervosa (AN) is defined by the persistent restriction of energy intake relative to requirements, leading to significantly low-body weight, an intense fear of gaining weight or becoming fat.¹ AN has the highest mortality rate of all psychiatric disorders and is associated with severe and frequent comorbid psychiatric and somatic complications.^{2,3} AN remains poorly understood and one of the main challenges is the identification of factors involved in the pattern of chronicity, relapse and severity.⁴ AN has a high genetic component with an heritability of about 0.7.⁵ As up to 63% of patients have a lack of recognition of the seriousness of the current low-body weight,^{6,7} AN should be evaluated not only through the verbal expression of symptoms, but also through more reliable endophenotypes. The approach based on endophenotypes could indeed allow a better understanding of the physiopathology of this complex disorder and facilitate the identification of the genes involved. Endophenotypes may be more suitable for detecting risk genes, because they are genetically less complex than phenotypes (that is, related to fewer genes than phenotypes).⁸

Recent studies support the idea that AN could be the consequence of aberrant reward processing⁹ and, combined with exaggerated control, could involve neural circuits implicated in reward processing and compulsivity.¹⁰ Altered patterns of brain activity associated with emotional and reward processing tasks, related to more or less specific stimuli of the illness, have provided important information about the mechanisms underlying AN symptoms.¹¹ It has been suggested that thinness could have a reward value in AN. Disturbance of the body image perception—classically

described as a misconception and a major dissatisfaction of the own body—is a key diagnostic criterion in AN, which could be involved in the development, maintenance and relapse of the disorder.¹²

In two functional magnetic resonance imaging (fMRI) studies, Fladung *et al.*¹³ observed a specific reward pattern distinguishing patients with AN from healthy participants during self-referent processing of visual stimuli cuing for starvation in adult¹³ and in adolescent¹⁴ patients. During the task, AN patients reported most positive feelings while processing underweight stimuli and showed higher activation in the ventral striatum compared with controls. The ventral striatum is a brain region known for its major involvement in the reward circuit.^{15,16} Nevertheless, the specificities of the emotional response to the female body shape (from starvation to overweight) remain insufficiently studied in AN, especially as the previous results are not really compatible with the proposition that an 'anhedonic profile' is characteristic of patients with AN.¹¹ To resolve this paradox between 'anhedonic profile' and the 'hedonic profile' regarding high activation of the reward system and emotional response to starvation body shape in AN patients, it was more broadly proposed that AN could be linked to a global alteration of reward and emotional information processing, including the integration of cognitive and physiological components of emotion.^{11,17,18} The neurocognitive specificities of the response to starvation in AN could therefore potentially constitute an endophenotype.

We initially detected an excess of the Met allele in 1142 Caucasian patients with eating disorder (including AN) consecutively

¹Clinique des Maladies Mentales et de l'Encéphale (CMME), Hospital Sainte-Anne, Paris-Descartes University, Paris, France; ²Centre of Psychiatry and Neuroscience, INSERM UMR 894, Paris, France and ³Department of Psychiatry and Psychotherapy, University of Ulm, Ulm, Germany. Correspondence: Professor P Gorwood, CMME, Hospital Sainte-Anne, Paris-Descartes University, 100 rue de la Santé, Paris 75014, France.

E-mail: p.gorwood@ch-sainte-anne.fr

Received 11 September 2015; revised 19 February 2016; accepted 12 March 2016

recruited from five European countries.¹⁹ Using a family-based association study in 453 trios, we replicated the excess of the Met66 allele in patients with AN, restrictive type.²⁰ The role of the BDNF gene in AN could be related to its role in reward functions. Indeed, in a recent study analyzing the role of the BDNF Val66Met polymorphism in reward-related brain function in adolescents, a significantly lower BOLD response in the striatum was detected in Val/Val compared with Met allele carriers during reward anticipation,²¹ and BDNF Met66 carriers showed increased BOLD responses during anticipation of monetary losses in the ventral tegmental area–nucleus accumbens–medial prefrontal cortex (VTA–NAc–mPFC) circuit in healthy adult controls.²² Animal studies could support an important role of BDNF in rewarding processing, as increased BDNF levels within the ventral tegmental area induced an opiate dependent-like reward state²³ and BDNF expression in the striatum explains part of voluntary alcohol consumption²⁴ in rats. Furthermore, this functional Val66Met (rs6265) polymorphism has been associated with inter-individual human variations in reward processing.²⁵

The aim of the present study was to assess the rewarding emotional response to starvation in patients with AN. Following the work of Fladung *et al.*¹³ and using their previously validated paradigm, we assessed the characteristics of the cognitive, emotional and physiologic response toward disease-specific pictures of female body shapes, in adult AN patients compared with healthy control (HC) women. We also investigated the possible contribution of the functional BDNF Val66Met polymorphism as a modulator of emotional response to starvation in AN.

MATERIALS AND METHODS

Participants

The sample included 71 adult females suffering from AN and 20 female HC participants, who agreed to participate in the study. Patients were recruited at the Clinique des Maladies Mentales et de l'Encéphale (CMME), a specialist care center for eating disorders (Hôpital Sainte-Anne, Paris, France), after entering specific treatment programs. All participants in the AN group were diagnosed with AN as outlined in the fifth edition of the Diagnostic and Statistical Manual of Mental Disorders.^{1,26} The healthy comparison participants were matched to patients with AN according to sex, age and education level.

Controls were all voluntary women from the general population, friends of acquaintances of patients. They were initially contacted by phone and then recruited and assessed by the principal investigator. To be eligible as a control, participants had to have no past or current eating disorder. Exclusion criteria for all participants were the following: age < 18, neurological disease, severe current somatic illness, hearing and visual impairments and current pregnancy.

All patients and controls reported Caucasian continental origins based on the country of birth of their four grandparents (inclusion criteria).

All participants gave their written informed consent to participate in the study, after a detailed explanation of its procedures. The protocol was approved by the regional ethic committee (Comité de Protection des Personnes).

Among AN patients, 36 (50.7%) were hospitalized at the time of assessment and 35 (49.3%) were outpatients. Thirty six (50.7%) patients had the diagnostic criteria of the restricting type, all others ($N=35$, 49.3%) having the binge eating/purging type. None of the participants had a diagnosis of schizophrenia, psychosis not otherwise specified, current major depressive episode, bipolar disorder or binge eating disorder. Concerning other psychiatric comorbidities, there were 10 (14.1%) patients with a lifetime diagnosis of social phobia, 9 (12.7%) with dysthymia, 16 (22.5%) with generalized anxiety disorder and 3 (4.2%) with obsessive-compulsive disorder. None of the participants had substance addiction, except for tobacco. Regarding psychotropic medication, 25 (35.2%) patients were treated with benzodiazepines, 28 (39.4%) with antidepressant treatment (SSRI or SNRI-type) and 17 (23.9%) with antipsychotic treatment. Twenty seven patients (38.0%) were not receiving any psychotropic medication. The 20 HCs declared that they have no neurological disorder, severe physical illness nor receiving any psychotropic medication.

Clinical assessment

Participants completed a structured diagnostic interview using the Mini International Neuropsychiatric Interview.²⁷ Psychotropic and non-psychotropic medications were also recorded.

Participants completed the Eating Attitude Test^{28,29} and the Bulimic Investigatory Test, Edinburgh,³⁰ assessing current, minimal and maximal body mass index (BMI) and amenorrhea. They also completed the Body Shape Questionnaire (BSQ)³¹ to measure concerns on body perception.

Procedure of paradigm

Stimulus material. The experimental protocol was rolled out in line with the paradigm of visual stimulation previously used.¹³ The paradigm consisted of four successive sessions, with a total of 120 images being presented to the participant, in a randomized order. The 120 stimuli were computer-generated, representing a naked woman (height 165 cm), varying in BMI, with an underweight (BMI: 12–16 kg/m²), normal weight (BMI: 19–23 kg/m²) and overweight (BMI: 26–30 kg/m²) figure. Images were presented in four different angles (15°, 25°, 35° and 45° of rotation to the right or left).

Tasks. Two tasks were proposed to the participant. The neutral control task was a 'categorization' task, which required the participants to estimate the weight of each visual stimulus from 1 to 4 on the numeric keyboard (corresponding to weight categories of 30, 45, 60 and 75 kg). The 'appraisal' task measured the appraisal of emotion in a self-referring way, answering the question 'How would you feel if you had the same shape?' Participants had to score their feeling during processing of each visual stimulus from 1 ('very bad') to 4 ('very good') on the numeric keyboard.

Physiological recording. Each participant was seated comfortably in a quiet room, with a 17-inch screen and recording material. For each participant, data were recorded 2 h after food intake (morning breakfast or midday lunch or snack only) to limit the potential effect on skin conductance recording of (1) postprandial satiety, (2) fasting and (3) caffeine intake. The autonomic measures were monitored using a 16-channel PowerLab system (AD Instruments, Bella Vista, NSW, Australia) connected to a PC. The biololectrical signals were filtered and amplified before being fed into the analog input connector of the PowerLab unit. Skin conductance was recorded with the ML116 GSR Amplifier (AD Instruments) of the 16-Channel PowerLab system, which provides a low and constant-voltage AC excitation. The dry electrodes were attached with a Velcro strap on the palmar surfaces of the distal phalanx of the second and third fingers of the non-dominant hand. Measurements were displayed in μ Sv. In this study, there were two measures of electrodermal response (SCR): the average number of electrodermal responses, defined as a change of at least 0.04 μ Sv from baseline, and the amplitude of the responses in μ Sv. Skin conductance was scored as changes in conductance starting in the 1–4-s intervals after onset of each visual stimulus. Prior to measurements, electrodermal activity at baseline level was defined by a recording in the presence of a neutral visual stimulus.

Genotyping

Genetic analyses were carried out on saliva samples (Oragene kit, DNA Genotek, Ottawa, ON, Canada), and DNA was extracted using standard methods. BDNF Val66Met polymorphism (SNP annotated rs6265) was performed using TaqMan SNP genotyping assay (Applied Biosystems, Life Technologies, Thermo Fisher Scientific, Waltham, MA, USA), detected on a real-time PCR DNA Engine OpticonTM 2 system (BIO-RAD, Hercules, CA, USA). Blanks and samples with known BDNF genotypes were taken along as quality controls during genotyping.

Statistics

All statistical analyses were conducted using SPSS version 17.0 for Windows (IBM, Armonk, NY, USA). Clinical variables were analyzed using Student's two-sample *t*-tests to assess the effect of the groups. The normal distribution of all the data was first verified. Analyses of variance and pairwise comparisons were conducted to compare intra- and intergroup effects on both explicit behavioral and implicit autonomic measures. Pairwise comparisons were performed using a Bonferroni correction for multiple tests. Analyses of the relationships between BDNF Val66Met alleles and the SCR response frequency were performed using linear regression models.

Table 1. Demographic and clinical characteristics of patients with anorexia nervosa and healthy control women

Characteristics	Patients with anorexia nervosa (N = 71)			Healthy controls (N = 20)			t-test	df	P
	Mean	s.d.	Min-max	Mean	s.d.	Min-max			
Age (years)	27.4	9.1	18–54	27.2	9.2	18–53	0.08	89	0.94
Current body mass index (kg/ m ²)	17.5	2.1	12.8–21.1	20.9	1.2	18.5–24	7.38	89	< 0.001
Lowest lifetime body mass index (kg/ m ²)	13.3	1.9	9.2–17.1	19.8	1.8	17.7–23.3	14.27	89	< 0.001
Highest lifetime body mass index (kg/ m ²)	21.7	4.4	16.7–46.1	22.2	2.3	18.3–26.3	0.64	89	0.52
Age at onset (years)	18.5	6.1	9.0–44	—	—	—	—	—	—
Duration of illness (years)	6.30	7.63	0.3–32	—	—	—	—	—	—
Body Shape Questionnaire scores	117.4	37.4	47–188	77.8	25.7	44–131	5.39	85	< 0.001
Eating Attitude Test 40	41.4	25.8	3.0–95	6.4	4.0	3.0–15	14.5	65	< 0.001
Bulimic Investigatory Test, Edinburg symptoms	14.9	8.2	1.0–28	1.4	1.3	0.0–4.0	20.98	65	< 0.001
Bulimic Investigatory Test, Edinburg severity	4.5	5.2	0.0–21	0.5	1.0	0.0–2.0	4.39	65	0.04

Abbreviation: df, degree of freedom.

Table 2. Genetic distributions of the *BDNF* rs6265 variant of patients with anorexia nervosa and healthy control women

Characteristics for the <i>BDNF</i> rs6265	Patients with anorexia nervosa (N = 71)		Healthy controls (N = 20)		X ²	df	P
	N	%	N	%			
Allele distribution for Met allele	32/142	22.5	9/40	22.5	0	1	1
Allele distribution for Val allele	110/142	77.5	31/40	77.5			
Genotype distribution for Met/Met and Val/Met	29/71	40.8	7/20	35	0.22	1	0.637
Genotype distribution for Val/Val	42/71	59.2	13/20	65			

Abbreviation: df, degree of freedom.

RESULTS

Recruited population and *BDNF* genetic polymorphisms

Ninety one participants were included in the protocol, with 71 AN patients and 20 HC (Table 1). Patients and HCs were not significantly different for age and education, all of them being female. Clinical characteristics of AN patients and controls are described in Table 1, with, as expected, lower minimum and current BMIs, and higher BSQ score for patients with AN. The distributions of the *BDNF* rs6265 genotypes were in Hardy-Weinberg Equilibrium in both groups (AN: $P = 0.900$, HC: $P = 0.702$). Twenty nine of 71 (40.8%) AN patients and 7 of 20 (35.0%) HC had at least 1 Met allele. AN and HC participants did not significantly differ in terms of genotype ($\chi^2 = 0.2$, $P = 0.637$) or allele ($\chi^2 = 0.0$, $P = 1.000$) distributions (Table 2).

Categorization task

During the assessment of weight, AN patients estimated the weight of the underweight (AN 1.79 ± 0.22 versus HC 1.6 ± 0.3 ; $P = 0.005$) and the normal weight (AN 3.2 ± 0.3 versus HC 3.0 ± 0.2 ; $P = 0.012$) stimuli to be higher compared with HC. Groups did not differ concerning weight estimation of overweight stimuli (AN 3.8 ± 0.2 versus HC 3.9 ± 0.1 ; $P = 0.475$) (Supplementary Figure 1).

Subjective emotion ratings

The rating scores of the 'appraisal' task were different between the two groups ($F = 39.6$, degree of freedom (df) = 2, $P < 0.001$) (Table 3, Figure 1). Inter-group comparisons revealed that patients with AN, compared with HC, had higher positive scores for the underweight stimuli (2.7 ± 0.5 versus 1.9 ± 0.3 ; $P < 0.001$), and lower positive scores for both the normal and the overweight stimuli (1.9 ± 0.5 versus 2.6 ± 0.5 ; $P < 0.001$ and 1.1 ± 0.1 versus 1.3 ± 0.5 ; $P < 0.001$, respectively). Interestingly, the difference of positive feelings during processing of underweight stimuli in

patients compared with controls (average = 0.8, s.d. = 0.2) was significantly more pronounced than the difference of negative feelings during processing of overweight stimuli in patients compared with controls (average = 0.2, s.d. = 0.4) ($P < 0.001$).

Intra-group comparisons revealed that patients with AN rated the processing of underweight stimuli more positive compared with normal- and overweight stimuli ($P < 0.001$) (Figure 1). They also exhibited higher positive scores for normal weight stimuli compared with overweight stimuli ($P < 0.001$). HC women had higher positive scores for normal weight stimuli compared with underweight ($P < 0.001$) and overweight stimuli ($P < 0.001$).

Electrophysiological assessments

A significant group effect ($F = 7.6$, df = 2, $P = 0.007$) was observed for the average frequency of SCR during processing of the visual stimuli. Thus, AN patients reacted more to all stimuli when compared with HC women. Inter-group comparisons revealed that patients with AN reacted more to underweight stimuli compared with HC participants (0.4 ± 0.2 versus 0.2 ± 0.1 , $F = 23.0$, $P < 0.001$). This difference was not observed for normal (0.3 ± 0.4 versus 0.2 ± 1.0) and overweight (0.3 ± 0.2 versus 0.2 ± 0.1) stimuli (Table 3, Figure 2). Intra-group comparisons showed significant differences within the AN group. Patients reacted more to underweight stimuli compared with normal ($P < 0.001$) and overweight stimuli ($P < 0.001$). There was no significant difference in average frequency of SCR between the visual stimuli in the HC group (Figure 2).

We found significant differences in amplitude of SCR between the two groups (Table 3 and Supplementary Figure 2). AN patients had smaller response amplitude to underweight stimuli (0.5 ± 0.4 versus 0.9 ± 0.6 , $F = 11.4$, $P = 0.001$) and overweight stimuli (0.5 ± 0.4 versus 0.8 ± 0.6 , $F = 5.9$, $P = 0.017$) (Supplementary Figure 2). Intra-group comparisons showed no significant effect of the overall stimuli on the SC amplitude in patients and HC women. No

Table 3. Characteristics of the emotional and electrophysiological response to weight stimuli in anorexia nervosa and healthy controls groups

Visual stimuli	Responses	Patients with anorexia nervosa (N = 71)				Healthy controls (N = 20)				Genotypes (all participants)				Current BMI effect	Group	Genotype	Interaction between genotype and group
		All (N = 71)				All (N = 20)				Met+ (N = 20)							
		Met+ (N = 29)				Met- (N = 42)				Met+ (N = 13)							
		Average	s.d.	Average	s.d.	Average	s.d.	Average	s.d.	Average	s.d.	Average	s.d.	P-value	P-value	P-value	P-value
Underweight	Feel task	2.8	0.4	2.7	0.5	2.7	0.5	2.0	0.2	1.8	0.3	1.9	0.3	0.002	< 0.001	0.248	0.323
	SC+	0.5	0.2	0.3	0.2	0.4	0.2	0.2	0.1	0.2	0.1	0.2	0.1	0.079	< 0.001	0.169	0.287
Normal weight	SC amplitude	0.5	0.4	0.5	0.4	0.5	0.4	1.0	0.7	0.8	0.6	0.9	0.6	0.242	0.001	0.187	0.354
	Feel task	1.7	0.6	1.9	0.5	1.9	0.5	2.5	0.6	2.6	0.4	2.6	0.5	0.269	< 0.001	0.279	0.794
Overweight	SC+	0.4	0.5	0.3	0.3	0.3	0.4	0.3	0.1	0.2	0.4	0.2	1.0	0.018	0.347	0.294	0.938
	SC amplitude	0.8	0.1	0.5	0.6	0.6	0.4	0.7	0.4	0.6	0.4	0.7	0.6	< 0.001	0.838	0.373	0.635
	Feel task	1.1	0.1	1.1	0.1	1.1	0.1	1.5	0.7	1.3	0.3	1.3	0.5	0.013	< 0.001	0.044	0.074
	SC+	0.3	0.2	0.3	0.2	0.3	0.2	0.3	0.2	0.2	0.1	0.2	0.1	0.478	0.095	0.233	0.938
		0.5	0.4	0.5	0.5	0.5	0.4	0.7	0.3	0.9	0.7	0.8	0.6	0.242	0.017	0.579	0.289

Abbreviations: BMI, body mass index; SC+, skin conductance response (average frequency); SC amplitude, skin conductance amplitude.

Figure 1. The BMI of the stimuli were ranging between 12 and 30. As initially proposed (Fladung *et al.*,¹³) these stimuli were gathered in three groups with underweight (BMI between 12 and 16), normal weight (17 and 23) and overweight (26 to 30). The feelings could be rated from very bad feelings (1) to very good feelings (4), with no in-between indications (ratings 2 and 3). * $P < 0.05$, *inter and intra-group significant differences. AN, anorexia nervosa; BMI, body mass index; HC, healthy controls. **Figure 2.** Average frequency of skin conductance reactivity to visual stimuli (underweight, normal weight and overweight) in anorexia nervosa (AN) and healthy control (HC) groups. * $P < 0.05$, *inter and intra-group significant differences.

difference on any physiological data was found for electrophysiological response to weight stimuli between AN patients with and without medication (Supplementary Table 1). Furthermore, no difference was found for emotional and electrophysiological response to underweight stimuli between AN patients with restrictive type versus those with the binge eating/ purging type (Supplementary Table 2).

Genetics and emotional response

We investigated the characteristics of the emotional response to processing of all stimuli (emotional and cognitive) in Met *BDNF* carriers compared with Val/Val participants, in both AN patients and the HC group (Table 3 and Figure 3). Present BMI, age and being or not hospitalized were not significantly associated with *BDNF* genotypes. No genotype effect was found on the average frequency of SCR while processing the three stimuli. Furthermore, no interaction between genotype and AN disease on the average

Figure 3. Average frequency of skin conductance reactivity to underweight in Val (Val/Val) and Met carriers (Val/Met and Met/Met) in patients with anorexia nervosa (AN) ($N=71$) and in healthy controls (HCs) ($N=20$). * $P < 0.05$

frequency of SCR was found during processing of underweight stimuli (Supplementary Table 3).

In patients with AN subgroup analysis, Met carriers (Val/Met and Met/Met) had a significant increased frequency of SCR during processing of the underweight stimuli compared with Val homozygotes (0.5 ± 0.2 versus 0.3 ± 0.2 , $P=0.013$) (Figure 3). In the HC group, there was no genotypic effect on the frequency of SCR (0.2 ± 0.1 versus 0.2 ± 0.1 ; $P=0.588$). We detected no significant correlation between clinical dimensions and subjective electrophysiological responses to underweight stimuli (Supplementary Table 4). We computed a linear regression model for the AN patients group to study the relationship between emotional response during processing of the underweight stimuli, the Met allele of the *BDNF* and different clinical criteria (age, current BMI, minimal BMI, psychotropic medication, subtype of AN, number of hospitalizations, duration of illness and severity score of the BSQ) (Supplementary Table 5). The average frequency of SCR during processing of underweight stimuli was still significantly associated with the presence of the Met allele ($P=0.008$) even when these clinical characteristics of AN were included in such multivariate analysis. The Met allele was associated with an increased SCR in response cues for starvation in AN patients but not in HC participants.

DISCUSSION

The aim of this study was to investigate the cognitive, rewarding emotional and electrophysiological response during processing of under-, normal- and overweight stimuli in patients with AN compared with HC. We also assessed the role of the functional *BDNF* Val66Met polymorphism as a modulator of the rewarding emotional response to thinness.

Subjective ratings in both groups showed that patients with AN had more positive feelings scores compared with HC when they were processing underweight stimuli, although patients overestimated this weight. Furthermore, patients with AN reported a higher positive value of processing of underweight stimuli, which was more pronounced than a negative value of processing overweight stimuli. SCR also differed significantly in frequency and amplitude in AN patients compared with HC participants and the SCR frequency was higher during the exposure to images of underweight bodies. In AN patients, a smaller amplitude of SCR could be linked to undernutrition or related physical condition. The higher frequency of SCR to underweight stimuli is associated with lower amplitude, it is therefore difficult to depict which one

of these two aspects is more relevant to explain the salience of such specific visual stimuli. Last, the Met allele of the *BDNF* gene was specifically associated with an increased frequency of SCR during the exposure to thinness.

In a fMRI study proposing images of underweight bodies, the crucial brain region of the ventral striatum showed differential activity in participants with and without AN.¹³ Furthermore, another fMRI study performed in adolescents with AN and HCs reported more positive feeling in AN while facing underweight shapes. Relative to controls, underweight stimuli were already associated with greater activity of the ventral striatum, and processing of normal-weight stimuli elicited already reduced signaling, referring to the development of the disorder over time.¹⁴ Finally, the motivational salience of underweight shapes in patients with AN has been investigated in an electroencephalography study.³² Compared with normally developing adolescent girls, young AN patients presented a differential late positive potential pattern when viewing underweight women pictures. These results suggest an increased attention and motivation toward underweight stimuli in AN. The motivational salience of underweight stimuli in patients with AN seems to be particularly relevant and may promote pathological behaviors, maintaining starvation in patients. AN has often been described as the consequence of the fear to become fat or gain weight. A significant finding of this study is that patients with AN showed a pattern of emotional response, concerning both cognitive and electrophysiological aspects, showing a 'preference for underweight' which was more specific than the 'avoidance of overweight'. In addition to the cognitive measure of the emotional response, physiological measures were used to limit the 'positive expectations' bias and social desirability. Further, the use of skin conductance measurements seems relevant for patients with introspective capacities that might be altered.

Association involving the *BDNF* Val66Met variant and AN in a large case-control study showed a significant role of the *BDNF* in eating disorders.²⁰ In a study investigating 481 healthy adults, it has been reported that the Met/Met genotype carriers have a lower BMI compared with the Val/Met and Val/Val carriers.³³ Nevertheless, a case-control study and a meta-analysis, including nine studies, have shown that the Val66Met variant was not associated with AN at detectable levels,³⁴ a negative report which was recently confirmed by Boroska *et al.*³⁵ who performed a genome-wide association study in 2907 cases with AN from 14 countries and 14 860 matched controls. The data in the literature are thus contradictory and the association between the Val66Met polymorphism and AN seems controversial. This finding could be due to the significant clinical heterogeneity of the disorder and could strengthen the interest of studying more specific biomarkers to further understand the condition. The Val66Met variant rs6265 is associated with a decreased secretion of mature BDNF.³⁶ Altered BDNF levels, modulated by *BDNF* gene variability, are associated with the susceptibility to eating disorders, providing physiological evidence that BDNF could play a role in the development of AN and modulate eating behaviors and body weight regulations.³⁷ This disturbed circulating levels of BDNF in patients with AN may help maintain starvation through its impact on the central pathways modulating reward.³⁸ Here, we did not find any association between the Met allele of *BDNF* and AN, neither did we observe an effect of this allele and the 'feel task' assessments when facing different stimuli. More automatic (neuro-vegetative) tests of reward processing were indeed more informative.

Attempting to better understand the determinants of the emotional response to starvation in AN, we computed a linear regression model including the Met allele of the *BDNF* and many clinical characteristics of the illness. The SCR frequency during processing of underweight stimuli was significantly associated with the presence of the Met genotype but not with any of the

clinical criteria of AN included in the model. The Met allele of the *BDNF* gene could partly mediate the observed higher reward value of starvation in patients with AN. The neurocognitive specificities of the response to thinness in AN may therefore constitute a candidate biological/endophenotypic marker.

Our study has several limitations. First, the size of 20 HCs can be considered as modest compared with the group of 71 AN patients. Nevertheless, the controls have been carefully screened for eating and other psychiatric disorders and matched to patients for different characteristics. Second, to study the specificities of the emotional response to starvation in AN, we included in this study women with heterogeneous clinical profiles. Weight status, psychiatric comorbid conditions or current medication could be important modulators of the emotional response in these patients, and we wanted to study the reward value of starvation in a representative population of patients encountered in clinical practice. In our study, 35 AN patients had a BMI ≥ 17.5 kg/m², constituting a subgroup of patients fulfilling the criteria for subsyndromal AN (F50.1). All of them were treated for syndromic AN, but some had gained weight at the time of study entry. Even though we did not find a significant role of the present BMI, comparative electrodermal response to starvation in patients at both acute AN and after weight restoration would be an important topic to explore. During the task, patients overestimated the weight when they were processing underweight stimuli. The overall higher arousal might have influenced the stimulus-processing in patients with AN, and other non-body stimuli (from low to high arousal) could be included in the paradigm to confirm this observation. Finally, we were not able to control the participants' gaze direction during the execution of the paradigm. An eye-tracker processing may have been used to ensure that the emotional response was indeed due to the visual stimuli paradigm. When checking the coherence of results for each patient, as the paradigm was repeated more than once, we nevertheless did not find obvious inconsistencies.

There is an established model of reward processing that proposes three relevant components: liking (the hedonic aspect, you emphasize), wanting (the more action relevant aspect in terms of approaching behavior) and learning (referring to the development of processes).³⁶ Thereby any attempt to disentangle the aspects of liking would have the fundamental requirement that these aspects are orthogonal to each other on both a conceptual and neurobiological level. However, this assumption does not appear to be appropriate, as a review on this topic concludes.³⁹ Neurobiologically, the same neurochemical agent can be involved in processing of wanting and liking depending on its site of injection, which, for example, has been shown by microinjection of opioid agonists in the ventral striatum. In so-called 'hot-spots' liking and wanting reactions toward food in the rat were potentiated. Beyond these spots, however, only wanting, but not the liking reaction was enforced. Conceptually, if one interprets the liking aspect in a sense of assigning valence to a reward there is also a strong linkage between both aspects of 'liking' and 'approaching rewards' on that level. An interesting exception of this is 'irrational wanting', which can be induced in the animal through direct manipulations of the dopaminergic system via microinjections of amphetamine in the nucleus accumbens or drugs, activating catecholamine processing. This enforces the wanting but not the liking reaction, whereby the reward value reflects cue-triggered incentive-salience wanting which is sufficiently mediated by a subcortical neural reward system and does not need declarative goals or elaborative cognitive expectations activating cognitive cortical regions.⁴⁰

In summary, a higher positive value of starvation, rather than more negative value of overweight, might more accurately define patients with AN. The Met allele of the *BDNF* gene could partly mediate the observed higher reward value of starvation in AN patients. Disturbed processes of emotional and reward response

to starvation may thus promote strategies for maintaining pathological behaviors in patients with AN. Further studies are needed to explore the underlying neuronal mechanisms and the evolutionary terms of this response. It would help to better understand the mechanisms involved in the persistence of the disorder.

CONFLICT OF INTEREST

The authors declare no conflict of interest.

ACKNOWLEDGMENTS

We acknowledge the units of eating disorders at the CMME from Hôpital Sainte-Anne, Paris. JC was supported by the Fonds d'Etudes et de Recherche du Corps Médical (FERCM). During the last 5 years PG received research grants from Eli Lilly and Servier, and fees for presentations at congresses or participation in scientific boards from AstraZeneca, Bristol-Myers-Squibb, Janssen, Lilly, Lundbeck, Otsuka, Roche and Servier.

REFERENCES

- 1 American Psychiatric Association. *Diagnostic and Statistical Manual of Mental Disorders, 5th edn (DSM-V)*. American Psychiatric Publishing: Arlington, VA, 2013.
- 2 Papadopoulos FC, Ekblom A, Brandt L, Ekselius L. Excess mortality, causes of death and prognostic factors in anorexia nervosa. *Br J Psychiatry* 2009; **194**: 10–17.
- 3 Arcelus J, Mitchell AJ, Wales J, Nielsen S. Mortality rates in patients with anorexia nervosa and other eating disorders. A meta-analysis of 36 studies. *Arch Gen Psychiatry* 2011; **68**: 724–731.
- 4 Steinhausen H-C. The outcome of anorexia nervosa in the 20th century. *Am J Psychiatry* 2002; **159**: 1284–1293.
- 5 Gorwood P, Kipman A, Foulon C. The human genetics of anorexia nervosa. *Eur J Pharmacol* 2003; **480**: 163–170.
- 6 Couturier J, Lock J. What is recovery in adolescent anorexia nervosa? *Int J Eat Disord* 2006; **39**: 550–555.
- 7 Abbate-Daga G, Delsedime N, Nicotra B, Giovannone C, Marzola E, Amianto F et al. Psychosomatic syndromes and anorexia nervosa. *BMC Psychiatry* 2013; **13**: 14.
- 8 Gottesman II, Gould TD. The endophenotype concept in psychiatry: etymology and strategic intentions. *Am J Psychiatry* 2003; **160**: 636–645.
- 9 Kaye WH, Fudge JL, Paulus M. New insights into symptoms and neurocircuit function of anorexia nervosa. *Nat Rev Neurosci* 2009; **10**: 573–584.
- 10 Park RJ, Godier LR, Cowdrey FA. Hungry for reward: how can neuroscience inform the development of treatment for Anorexia Nervosa? *Behav Res Ther* 2014; **62**: 47–59.
- 11 Keating C. Theoretical perspective on anorexia nervosa: the conflict of reward. *Neurosci Biobehav Rev* 2010; **34**: 73–79.
- 12 Halmi KA. Perplexities of treatment resistance in eating disorders. *BMC Psychiatry* 2013; **13**: 292.
- 13 Fladung A-K, Grön G, Grammer K, Herrnberger B, Schilly E, Grasteit S et al. A neural signature of anorexia nervosa in the ventral striatal reward system. *Am J Psychiatry* 2010; **167**: 206–212.
- 14 Fladung A-K, Schulze UME, Schöll F, Bauer K, Grön G. Role of the ventral striatum in developing anorexia nervosa. *Transl Psychiatry* 2013; **3**: e315.
- 15 Groenewegen HJ, Trimble M. The ventral striatum as an interface between the limbic and motor systems. *CNS Spectr* 2007; **12**: 887–892.
- 16 Van Kuyck K, Gabriëls L, Cosyns P, Arkens L, Sturm V, Rasmussen S et al. Behavioural and physiological effects of electrical stimulation in the nucleus accumbens: a review. *Acta Neurochir Suppl* 2007; **97**: 375–391.
- 17 Hatch A, Madden S, Kohn MR, Clarke S, Touyz S, Gordon E et al. Emotion brain alterations in anorexia nervosa: a candidate biological marker and implications for treatment. *J Psychiatry Neurosci JPN* 2010; **35**: 267–274.
- 18 Keating C, Tilbrook AJ, Rossell SL, Enticott PG, Fitzgerald PB. Reward processing in anorexia nervosa. *Neuropsychologia* 2012; **50**: 567–575.
- 19 Ribasés M, Gratacòs M, Fernández-Aranda F, Bellodi L, Boni C, Anderlüh M et al. Association of BDNF with anorexia, bulimia and age of onset of weight loss in six European populations. *Hum Mol Genet* 2004; **13**: 1205–1212.
- 20 Ribasés M, Gratacòs M, Fernández-Aranda F, Bellodi L, Boni C, Anderlüh M et al. Association of BDNF with restricting anorexia nervosa and minimum body mass index: a family-based association study of eight European populations. *Eur J Hum Genet* 2005; **13**: 428–434.
- 21 Nees F, Witt SH, Dinu-Biringer R, Lourdasamy A, Tzschoppe J, Vollstädt-Klein S et al. BDNF Val66Met and reward-related brain function in adolescents: role for early alcohol consumption. *Alcohol* 2015; **49**: 103–110.

- 22 Peciña M, Martínez-Jauand M, Love T, Heffernan J, Montoya P, Hodgkinson C *et al*. Valence-specific effects of BDNF Val66Met polymorphism on dopaminergic stress and reward processing in humans. *J Neurosci* 2014; **34**: 5874–5881.
- 23 Vargas-Perez H, Ting-A Kee R, Walton CH, Hansen DM, Razavi R, Clarke L *et al*. Ventral tegmental area BDNF induces an opiate-dependent-like reward state in naive rats. *Science* 2009; **324**: 1732–1734.
- 24 Bahi A, Dreyer JL. Striatal modulation of BDNF expression using microRNA124a-expressing lentiviral vectors impairs ethanol-induced conditioned-place preference and voluntary alcohol consumption. *Eur J Neurosci* 2013; **38**: 2328–2337.
- 25 Gasic GP, Smoller JW, Perlis RH, Sun M, Lee S, Kim BW *et al*. BDNF, relative preference, and reward circuitry responses to emotional communication. *Am J Med Genet B Neuropsychiatr Genet* 2009; **150B**: 762–781.
- 26 American Psychiatric Association. *Diagnostic and Statistical Manual of Mental Disorders*, 4th edn (DSM-IV). Washington DC, USA, 1994.
- 27 Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E *et al*. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. *J Clin Psychiatry* 1998; **59**: 22–33.
- 28 Garner DM. *Eating Disorder Inventory-2 professional manual*. Psychological Assessment Resources: Odessa, FL, USA, 1991.
- 29 Garner DM, Garfinkel PE. The eating attitudes test: an index of the symptoms of anorexia nervosa. *Psychol Med* 1979; **9**: 273–279.
- 30 Henderson M, Freeman CP. A self-rating scale for bulimia. The "BITE". *Br J Psychiatry* 1987; **150**: 18–24.
- 31 Cooper PJ, Taylor MJ, Cooper Z, Fairburn CG. The development and validation of the Body Shape Questionnaire. *Int J Eat Disord* 1986; **6**: 485–494.
- 32 Horndasch S, Heinrich H, Kratz O, Moll GH. The late positive potential as a marker of motivated attention to underweight bodies in girls with anorexia nervosa. *J Psychosom Res* 2012; **73**: 443–447.
- 33 Gunstad J, Schofield P, Paul RH, Spitznagel MB, Cohen RA, Williams LM *et al*. BDNF Val66Met polymorphism is associated with body mass index in healthy adults. *Neuropsychobiology* 2006; **53**: 153–156.
- 34 Brandys MK, Kas MJH, van Elburg AA, Ophoff R, Slof-Op't Landt MCT, Middeldorp CM *et al*. The Val66Met polymorphism of the BDNF gene in anorexia nervosa: new data and a meta-analysis. *World J Biol Psychiatry* 2013; **14**: 441–451.
- 35 Boraska V, Franklin CS, Floyd JaB, Thornton LM, Huckins LM, Southam L *et al*. A genome-wide association study of anorexia nervosa. *Mol Psychiatry* 2014; **19**: 1085–1094.
- 36 Egan MF, Kojima M, Callicott JH, Goldberg TE, Kolachana BS, Bertolino A *et al*. The BDNF val66met polymorphism affects activity-dependent secretion of BDNF and human memory and hippocampal function. *Cell* 2003; **112**: 257–269.
- 37 Mercader JM, Ribasés M, Gratacòs M, González JR, Bayés M, de Cid R *et al*. Altered brain-derived neurotrophic factor blood levels and gene variability are associated with anorexia and bulimia. *Genes Brain Behav* 2007; **6**: 706–716.
- 38 Monteleone P, Maj M. Dysfunctions of leptin, ghrelin, BDNF and endocannabinoids in eating disorders: beyond the homeostatic control of food intake. *Psychoneuroendocrinology* 2013; **38**: 312–330.
- 39 Berridge KC, Robinson TE, Aldridge JW. Dissecting components of reward: "liking", "wanting", and learning. *Curr Opin Pharmacol* 2009; **9**: 65–73.
- 40 Berridge KC. The debate over dopamine's role in reward: the case for incentive salience. *Psychopharmacology* 2007; **191**: 391–431.

This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>

Supplementary Information accompanies the paper on the Translational Psychiatry website (<http://www.nature.com/tp>)